These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 18279581)

  • 1. Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE).
    Schlander M
    Curr Med Res Opin; 2008 Apr; 24(4):951-66. PubMed ID: 18279581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2008 Feb; 24(2):515-35. PubMed ID: 18186971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
    Griffin SC; Weatherly HL; Richardson GA; Drummond MF
    Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.
    Schlander M
    Eur Child Adolesc Psychiatry; 2007 Oct; 16(7):421-9. PubMed ID: 17401606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
    Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
    CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder.
    Donnelly M; Haby MM; Carter R; Andrews G; Vos T
    Aust N Z J Psychiatry; 2004 Aug; 38(8):592-601. PubMed ID: 15298581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Update on Current Care guidelines: ADHD (attention-deficit/hyperactivity disorder, children and adolescents)].
    Käypä hoito suosituksen päivitystiivistelmä
    Duodecim; 2012; 128(5):539-40. PubMed ID: 22486070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NICE ADHD health technology assessment: a review and critique.
    Schlander M
    Child Adolesc Psychiatry Ment Health; 2008 Jan; 2(1):1. PubMed ID: 18197978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2007 Jan; 23(1):207-22. PubMed ID: 17261237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
    Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
    Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.